Sysmex Europe SE Unveils HISCL™ Platform for Alzheimer's Blood Testing

On June 17, 2026, Sysmex Europe SE announced the launch of its HISCL™ automated immunoassay system, designed for Alzheimer's blood biomarker testing. This platform offers speedy, completely automated, and gentle alternatives to conventional CSF and PET approaches, with test results ready in 17 minutes. Supported by independent European studies, it provides a promising solution for early detection of Aβ pathology using non-invasive blood samples.

The HISCL™ platform's diagnostic accuracy has been validated by leading research institutions, achieving AUROC values above 0.90, indicating an effective performance in identifying Alzheimer's-related amyloid pathology. Despite research advancements, many patients with mild cognitive impairment remain undiagnosed or misdiagnosed. Traditional diagnostic methods are often invasive and expensive, highlighting the significance of this new technology.

The system integrates seamlessly into existing laboratory setups, needing no specialist training. It aims to address the diagnostic gap by providing a scalable solution across various healthcare settings. Clinicians benefit from a more accessible, faster diagnostic tool, potentially transforming the patient diagnostic journey.